Multiple sclerosis as a generalized CNS disease—comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS

Multiple sclerosis as a generalized CNS disease—comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS2018-01-17T17:04:58-05:00

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring2018-01-17T17:03:31-05:00

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis2018-01-17T17:03:31-05:00

Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study2018-01-17T17:03:31-05:00

The Janus face of CNS-directed autoimmune response: a therapeutic challenge

The Janus face of CNS-directed autoimmune response: a therapeutic challenge2018-01-17T17:03:31-05:00

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis2018-01-17T17:00:50-05:00